Home LiteratureArticle Details
PMID: 11694153 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

JAMA ·Vol. 286 ·No. 17 ·2001-11-07 ·Pages 2120-7

Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME

Abstract

Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined. To assess the sensitivity and specificity with which cerebral metabolic patterns at a single point in time forecast subsequent documentation of progressive dementia. Positron emission tomography (PET) studies of [(18)F]fluorodeoxyglucose in 146 patients undergoing evaluation for dementia with at least 2 years' follow-up for disease progression at the University of California, Los Angeles, from 1991 to 2000, and PET studies in 138 patients undergoing evaluation for dementia at an international consortium of facilities, with histopathological diagnoses an average of 2.9 years later, conducted from 1984 to 2000. Regional distribution of [(18)F]fluorodeoxyglucose in each patient, classified by criteria established a priori as positive or negative for presence of a progressive neurodegenerative disease in general and of Alzheimer disease (AD) specifically, compared with results of longitudinal or neuropathologic analyses. Progressive dementia was detected by PET with a sensitivity of 93% (191/206) and a specificity of 76% (59/78). Among patients with neuropathologically based diagnoses, PET identified patients with AD and patients with any neurodegenerative disease with a sensitivity of 94% and specificities of 73% and 78%, respectively. The negative likelihood ratio of experiencing a progressive vs nonprogressive course over the several years following a single negative brain PET scan was 0.10 (95% confidence interval, 0.06-0.16), and the initial pattern of cerebral metabolism was significantly associated with the subsequent course of progression overall (P<.001). In patients presenting with cognitive symptoms of dementia, regional brain metabolism was a sensitive indicator of AD and of neurodegenerative disease in general. A negative PET scan indicated that pathologic progression of cognitive impairment during the mean 3-year follow-up was unlikely to occur.

MeSH Terms
Aged Brain/diagnostic imaging,metabolism Dementia/diagnosis,diagnostic imaging,physiopathology Disease Progression Female Fluorodeoxyglucose F18 Glucose/metabolism Humans Likelihood Functions Male Middle Aged Predictive Value of Tests Prognosis Radiopharmaceuticals Sensitivity and Specificity Tomography, Emission-Computed
Chemicals
Radiopharmaceuticals Fluorodeoxyglucose F18 Glucose
Authors & Affiliations
24 authors, click to expand affiliations / ORCID
Silverman D H
Ahmanson Biological Imaging Center, CHS AR-144, Department of Molecular and Medical Pharmacology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095-6942, USA. dsilver@ucla.edu
Small G W
Chang C Y
Lu C S
Kung De Aburto M A
Chen W
Czernin J
Rapoport S I
Pietrini P
Alexander G E
Schapiro M B
Jagust W J
Hoffman J M
Welsh-Bohmer K A
Alavi A
Clark C M
Salmon E
de Leon M J
Mielke R
Cummings J L
Kowell A P
Gambhir S S
Hoh C K
Phelps M E
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
0098-7484
Published
2001-11-07
Pages
2120-7
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Grants
NIA NIH HHS · AG10129 · United States
NIA NIH HHS · AG16570 · United States
NIA NIH HHS · P50 AG05128-07 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com